To Treat or Not to Treat? Cost-Effectiveness of Ace Inhibitors in Non-Diabetic Advanced Renal Disease - a Dutch Perspective

Publisher： Karger

E-ISSN： 1423-0143|37|2-3|168-180

ISSN： 1420-4096

Source： Kidney and Blood Pressure Research, Vol.37, Iss.2-3, 2013-05, pp. : 168-180

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antiproteinuric Effect of Losartan in Non-Diabetic Renal Disease Is Not Dependent on ACE Insertion/Deletion Polymorphism

By  

Kidney and Blood Pressure Research, Vol. 29, Iss. 4, 2006-11 ,pp. : 216-224

Karger

Access to resources Recommend Favorite

Modelling the Cost-Effectiveness of Delaying End-Stage Renal Disease

By  

Nephron, Vol. 133, Iss. 2, 2016-06 ,pp. : 89-97

Karger

Access to resources Recommend Favorite

Effects of Combination Treatment with Losartan and Trandolapril on Office and Ambulatory Blood Pressures in Non-Diabetic Renal Disease: A COOPERATE-ABP Substudy

By  

American Journal of Nephrology, Vol. 24, Iss. 5, 2004-12 ,pp. : 543-548

Karger

Access to resources Recommend Favorite

The Intron 4 Polymorphism in the Calcium-Sensing Receptor Gene in Diabetes Mellitus and its Chronic Complications, Diabetic Nephropathy and Non-Diabetic Renal Disease

By  

Kidney and Blood Pressure Research, Vol. 39, Iss. 5, 2014-10 ,pp. : 399-407

Karger

Access to resources Recommend Favorite

Use of Angiotensin-Converting Enzyme Inhibitors in Patients with Diabetic and Nondiabetic Chronic Renal Diseases: A Need for Reassessment

By  

Nephron, Vol. 80, Iss. 3, 1998-11 ,pp. : 367-368

Karger

Access to resources Recommend Favorite